Recent developments in oncology include a phase 3 trial where Roche’s combination of bispecific antibody Lunsumio and antibody-drug conjugate Polivy significantly improved progression-free survival in second-line large B-cell lymphoma, outperforming standard chemotherapy. Exelixis’ oral TKI zanzalintinib showed an overall survival benefit in colorectal cancer phase 3 trials, advancing its commercial prospects. Additionally, next-generation CAR-T cell designs address tumor heterogeneity and immunosuppressive microenvironments through multi-targeting and enhanced resistance to exhaustion, aiming to improve durability and safety profiles in lymphoma treatments.